[uPA/PAI-1 and EPClin® : Comparison of their impact on the management of intermediate-prognosis breast cancers].

Date publication

octobre 2021

Journal

Gynecologie, obstetrique, fertilite & senologie

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MATHELIN Carole

Tous les auteurs :
Maniez P, Osada M, Reix N, Mathelin C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34626849

Résumé

The uPA/PAI-1 assay and the EPClin® test are useful tools that add to clinico-anatomical characteristics to determine the indication of adjuvant chemotherapy in case of intermediate-prognosis invasive breast cancer. The principal purpose of our study was to analyze the concordance of uPA/PAI-1 and EPClin® in classification of patients into two groups: low and high risk of relapse.

Mots clés

EPClin® test, breast cancer, cancer du sein, chemotherapy, chimiothérapie, hormone therapy, hormonothérapie, test EPClin®, uPA/PAI-1

Référence

Gynecol Obstet Fertil Senol. 2021 Oct 6;: